Sarepta Therapeutic Is It A Buy

last updated on

Sarepta Therapeutic Is It A Buy

Sarepta Therapeutics: Is It A Buy After Massive Drop?

Sarepta Therapeutics (SRPT) is under heavy selling pressure as the stock dipped more than 20% in one trading day. The Sarepta Therapeutics (SRPT) mainly focuses on gene therapies.

It appears that the sell-off in Sarepta Therapeutics (SRPT) was a little bit overdone. That's why many are wondering if it's a good idea to jump into the Sarepta Therapeutics (SRPT) stock or not.

Elevidys Faces Setbacks

Sarepta Therapeutics is famous for its DMD medicine, which treats a rare genetic condition. This condition is known to cause weakening of the muscles, which can be treated by medicine from Sarepta Therapeutics.

Elevidys is the most important product of Sarepta Therapeutics. According to them, this therapy targets the genetic cause of DMD.

In 2024, the Elevidys got its approval in the USA for ambulatory patients. However, the Elevidys needs to pass at least 1 more trial to confirm its efficiency.

However, the company is already facing setbacks with its products. It was recently announced that one patient who received the treatment suffered from acute liver failure. The patient eventually died, which marked the first such case in the history of the Elevidys.

If the Elevidys is proven to be the cause of this death, it will have a major effect on the sales.

However, Sarepta Therapeutics is also working on other DMD treatments. The company is also working on the phase 3 clinical trial for treatment of limb-girdle muscular dystrophy.

Right now, there is a lot of uncertainty about whether the products of Sarepta Therapeutics will see the green light or not. As of now, things look difficult for Sarepta Therapeutics.

There's no doubt that DMD patients could benefit immensely from the product developed by Sarepta Therapeutics. However, it has yet to pass the trials, which means it is too soon to buy the Sarepta Therapeutics stock.

Trending Stories